Barr Gets License For Generic Actiq As FTC Clears Cephalon-Cima Merger

Law360, New York (August 11, 2004, 12:00 AM EDT) -- Cephalon Inc. has granted Barr Laboratories Inc. a license to create a generic version of the pain killer Actiq as part of a deal with antitrust authorities to clear the drug maker’s acquisition of Cima Labs Inc.

On Monday, the Federal Trade Commission decided not to prevent Cephalon's purchase of Cima Labs Inc. after the companies agreed to grant the license to Barr.

Cephalon could have been forced to divest itself of the product, but was able to retain the right to continue to market Actiq...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.